---
kind: "section"
citation: "21 C.F.R. § 607.31"
title: "21"
number: "607.31"
heading: "Additional blood product listing information."
url: "https://uscodex.org/cfr/21/607.31"
---

# §607.31. Additional blood product listing information.

- (a) In addition to the information routinely required by §§ [607.25](/cfr/21/607.25.md) and [607.30](/cfr/21/607.30.md), the Director of the Center for Biologics Evaluation and Research may require submission of the following information by letter or by Federal Register notice:
  - (1) For a particular blood product so listed, upon request made by the Director of the Center for Biologics Evaluation and Research for good cause, a copy of all advertisements.
  - (2) For a particular blood product so listed, upon a finding by the Director of the Center for Biologics Evaluation and Research that it is necessary to carry out the purposes of the act, a quantitative listing of all ingredients.
  - (3) For each registrant, upon a finding by the Director of the Center for Biologics Evaluation and Research that it is necessary to carry out the purposes of the act, a list of each listed blood product containing a particular ingredient.
- (b) [Reserved]

## Notes

### Amendments

[66 FR 59158, Nov. 27, 2001]

### Authority

Authority: 21 U.S.C. 321, 331, 351, 352, 355, 360, 371, 374, 381, 393; 42 U.S.C. 262, 264, 271.

### Source

Source: 40 FR 52788, Nov. 12, 1975, unless otherwise noted.

### Amendments

[66 FR 59158, Nov. 27, 2001]